Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Pasithea Therapeutics Corp ( (KTTA) ).
On January 28, 2026, Pasithea Therapeutics Corp. held a Special Meeting of Stockholders at which shareholders approved a substantial increase in the company’s capital structure and equity incentive capacity. Stockholders voted to amend the company’s certificate of incorporation to raise the number of authorized shares of common stock from 100,000,000 to 500,000,000, significantly expanding potential future issuance capacity, and separately approved an amendment to the 2023 Stock Incentive Plan to lift the maximum number of shares available under the plan by 11,985,779 to a total of 14,000,000 shares. The measures, both passed by majority votes with a quorum present, provide Pasithea with greater flexibility to issue equity for financing, strategic transactions, and employee or director incentives, which may support its growth and retention efforts but also increase the possibility of future shareholder dilution.
The most recent analyst rating on (KTTA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pasithea Therapeutics Corp stock, see the KTTA Stock Forecast page.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. operates in the therapeutics and biotechnology sector, focusing on the development of treatments for central nervous system and related disorders. The company uses equity-based incentive plans as part of its compensation and capital management strategy, reflecting its reliance on stock issuances to fund growth and retain talent in a development-stage, research-driven business.
Average Trading Volume: 7,266,090
Technical Sentiment Signal: Sell
Current Market Cap: $19.84M
For a thorough assessment of KTTA stock, go to TipRanks’ Stock Analysis page.